Vaccine approaches conferring cross-protection against influenza viruses.
Identifieur interne : 000370 ( PubMed/Corpus ); précédent : 000369; suivant : 000371Vaccine approaches conferring cross-protection against influenza viruses.
Auteurs : Sai V. Vemula ; Ekramy E. Sayedahmed ; Suryaprakash Sambhara ; Suresh K. MittalSource :
- Expert review of vaccines [ 1744-8395 ] ; 2017.
English descriptors
- KwdEn :
- MESH :
- chemical , immunology : Influenza Vaccines.
- chemical , isolation & purification : Influenza Vaccines.
- immunology : Orthomyxoviridae.
- methods : Drug Discovery.
- prevention & control : Influenza, Human.
- Cross Protection, Humans.
Abstract
Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of the currently available influenza vaccines are strong inducers of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants. Areas covered: Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have the potential to provide broad spectrum protection against influenza viruses. Expert commentary: Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.
DOI: 10.1080/14760584.2017.1379396
PubMed: 28925296
Links to Exploration step
pubmed:28925296Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Vaccine approaches conferring cross-protection against influenza viruses.</title><author><name sortKey="Vemula, Sai V" sort="Vemula, Sai V" uniqKey="Vemula S" first="Sai V" last="Vemula">Sai V. Vemula</name><affiliation><nlm:affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sayedahmed, Ekramy E" sort="Sayedahmed, Ekramy E" uniqKey="Sayedahmed E" first="Ekramy E" last="Sayedahmed">Ekramy E. Sayedahmed</name><affiliation><nlm:affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sambhara, Suryaprakash" sort="Sambhara, Suryaprakash" uniqKey="Sambhara S" first="Suryaprakash" last="Sambhara">Suryaprakash Sambhara</name><affiliation><nlm:affiliation>b Influenza Division , Centers for Disease Control and Prevention , Atlanta , GA , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mittal, Suresh K" sort="Mittal, Suresh K" uniqKey="Mittal S" first="Suresh K" last="Mittal">Suresh K. Mittal</name><affiliation><nlm:affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28925296</idno><idno type="pmid">28925296</idno><idno type="doi">10.1080/14760584.2017.1379396</idno><idno type="wicri:Area/PubMed/Corpus">000370</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000370</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Vaccine approaches conferring cross-protection against influenza viruses.</title><author><name sortKey="Vemula, Sai V" sort="Vemula, Sai V" uniqKey="Vemula S" first="Sai V" last="Vemula">Sai V. Vemula</name><affiliation><nlm:affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sayedahmed, Ekramy E" sort="Sayedahmed, Ekramy E" uniqKey="Sayedahmed E" first="Ekramy E" last="Sayedahmed">Ekramy E. Sayedahmed</name><affiliation><nlm:affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Sambhara, Suryaprakash" sort="Sambhara, Suryaprakash" uniqKey="Sambhara S" first="Suryaprakash" last="Sambhara">Suryaprakash Sambhara</name><affiliation><nlm:affiliation>b Influenza Division , Centers for Disease Control and Prevention , Atlanta , GA , USA.</nlm:affiliation></affiliation></author><author><name sortKey="Mittal, Suresh K" sort="Mittal, Suresh K" uniqKey="Mittal S" first="Suresh K" last="Mittal">Suresh K. Mittal</name><affiliation><nlm:affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Expert review of vaccines</title><idno type="eISSN">1744-8395</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cross Protection</term><term>Drug Discovery (methods)</term><term>Humans</term><term>Influenza Vaccines (immunology)</term><term>Influenza Vaccines (isolation & purification)</term><term>Influenza, Human (prevention & control)</term><term>Orthomyxoviridae (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cross Protection</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of the currently available influenza vaccines are strong inducers of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants. Areas covered: Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have the potential to provide broad spectrum protection against influenza viruses. Expert commentary: Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28925296</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8395</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2017</Year><Month>11</Month></PubDate></JournalIssue><Title>Expert review of vaccines</Title><ISOAbbreviation>Expert Rev Vaccines</ISOAbbreviation></Journal><ArticleTitle>Vaccine approaches conferring cross-protection against influenza viruses.</ArticleTitle><Pagination><MedlinePgn>1141-1154</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/14760584.2017.1379396</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of the currently available influenza vaccines are strong inducers of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants. Areas covered: Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have the potential to provide broad spectrum protection against influenza viruses. Expert commentary: Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vemula</LastName><ForeName>Sai V</ForeName><Initials>SV</Initials><AffiliationInfo><Affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sayedahmed</LastName><ForeName>Ekramy E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sambhara</LastName><ForeName>Suryaprakash</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>b Influenza Division , Centers for Disease Control and Prevention , Atlanta , GA , USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mittal</LastName><ForeName>Suresh K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>a Department of Comparative Pathobiology and Purdue Institute for Immunology , Inflammation and Infectious Disease, Purdue University , West Lafayette , IN , USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI059374</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>09</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Vaccines</MedlineTA><NlmUniqueID>101155475</NlmUniqueID><ISSNLinking>1476-0584</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056738" MajorTopicYN="Y">Cross Protection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Influenza viruses</Keyword><Keyword MajorTopicYN="Y">avian influenza viruses</Keyword><Keyword MajorTopicYN="Y">cross protection</Keyword><Keyword MajorTopicYN="Y">novel influenza vaccines</Keyword><Keyword MajorTopicYN="Y">pandemic influenza</Keyword><Keyword MajorTopicYN="Y">pandemic preparedness</Keyword><Keyword MajorTopicYN="Y">universal influenza vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>9</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28925296</ArticleId><ArticleId IdType="doi">10.1080/14760584.2017.1379396</ArticleId><ArticleId IdType="pmc">PMC6005355</ArticleId><ArticleId IdType="mid">NIHMS974409</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Ther. 2014 Jan;22(1):233-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23831594</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2009 Oct;99 Suppl 2:S225-30</Citation><ArticleIdList><ArticleId IdType="pubmed">19797736</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Apr 30;8(4):e62496</Citation><ArticleIdList><ArticleId IdType="pubmed">23638099</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1984 Mar;133(2):456-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6200990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2016 Jul 28;166(3):609-623</Citation><ArticleIdList><ArticleId IdType="pubmed">27453470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Mar 07;6:22666</Citation><ArticleIdList><ArticleId IdType="pubmed">26947245</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1995;13(15):1399-402</Citation><ArticleIdList><ArticleId IdType="pubmed">8578816</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2001 Feb 8;19(13-14):1794-805</Citation><ArticleIdList><ArticleId IdType="pubmed">11166905</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Microbiol Immunol. 2015;386:181-204</Citation><ArticleIdList><ArticleId IdType="pubmed">25059893</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2008 Apr 15;197(8):1185-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18462165</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):850-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21798894</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteins. 2013 Oct;81(10):1759-75</Citation><ArticleIdList><ArticleId IdType="pubmed">23625724</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Jan 2;31(2):436-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23387064</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2016 Jan 27;34(5):678-686</Citation><ArticleIdList><ArticleId IdType="pubmed">26691568</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2005 Oct 7;310(5745):77-80</Citation><ArticleIdList><ArticleId IdType="pubmed">16210530</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 2009 Jun 12;137(6):983-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19524497</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Aug 11;29(35):5911-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21723354</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Oct 4;357(14):1373-81</Citation><ArticleIdList><ArticleId IdType="pubmed">17914038</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Immunol. 2001 Aug 1;211(2):143-53</Citation><ArticleIdList><ArticleId IdType="pubmed">11591118</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Jan 1;52(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21148512</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2000 Dec 8;19(9-10):1180-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11137255</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2013 Jun;13(6):485-96</Citation><ArticleIdList><ArticleId IdType="pubmed">23518156</ArticleId></ArticleIdList></Reference><Reference><Citation>Monoclon Antib Immunodiagn Immunother. 2016 Aug;35(4):191-8</Citation><ArticleIdList><ArticleId IdType="pubmed">27463230</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2013 Apr;98(1):4-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23416215</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13538-43</Citation><ArticleIdList><ArticleId IdType="pubmed">18765801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Nov;88(22):13418-28</Citation><ArticleIdList><ArticleId IdType="pubmed">25210172</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Oct 16;8(10):e76318</Citation><ArticleIdList><ArticleId IdType="pubmed">24146855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Apr 1;186(7):4331-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21357542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2015;11(10):2359-69</Citation><ArticleIdList><ArticleId IdType="pubmed">26176592</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Aug 16;28(36):5837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20600478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2012 Jan;8(1):45-58</Citation><ArticleIdList><ArticleId IdType="pubmed">22251994</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2014 Feb;58(4):449-57</Citation><ArticleIdList><ArticleId IdType="pubmed">24280090</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1987 Feb;68 ( Pt 2):433-40</Citation><ArticleIdList><ArticleId IdType="pubmed">3493324</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 May 14;10(5):e0126650</Citation><ArticleIdList><ArticleId IdType="pubmed">25973787</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011 Mar 28;6(3):e18314</Citation><ArticleIdList><ArticleId IdType="pubmed">21464940</ArticleId></ArticleIdList></Reference><Reference><Citation>Monoclon Antib Immunodiagn Immunother. 2015 Dec;34(6):436-41</Citation><ArticleIdList><ArticleId IdType="pubmed">26683184</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 May 03;8(5):e62778</Citation><ArticleIdList><ArticleId IdType="pubmed">23658773</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Jun 12;27(29):3811-20</Citation><ArticleIdList><ArticleId IdType="pubmed">19406188</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Jul 1;204(1):124-34</Citation><ArticleIdList><ArticleId IdType="pubmed">21628666</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Sep 25;8(9):e75460</Citation><ArticleIdList><ArticleId IdType="pubmed">24086536</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Jul 26;29(33):5481-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21664216</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2002 Apr;83(Pt 4):723-34</Citation><ArticleIdList><ArticleId IdType="pubmed">11907320</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1990 Mar;64(3):1375-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2304147</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2009 Jun 24;4(6):e6032</Citation><ArticleIdList><ArticleId IdType="pubmed">19554101</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Feb 17;28(7):1740-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20034605</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Nov;88(22):13300-9</Citation><ArticleIdList><ArticleId IdType="pubmed">25210173</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2002 Aug;8(8):796-801</Citation><ArticleIdList><ArticleId IdType="pubmed">12141964</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2009 Apr 10;324(5924):246-51</Citation><ArticleIdList><ArticleId IdType="pubmed">19251591</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jan 15;33(4):577-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24176494</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2016 Jan 20;34(4):466-473</Citation><ArticleIdList><ArticleId IdType="pubmed">26709639</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Dec;79(23):14933-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16282492</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2008 Feb;82(3):1350-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18032492</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1998 May;177(5):1266-74</Citation><ArticleIdList><ArticleId IdType="pubmed">9593011</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Jun 26;33(29):3314-21</Citation><ArticleIdList><ArticleId IdType="pubmed">26026378</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Interv Aging. 2012;7:55-64</Citation><ArticleIdList><ArticleId IdType="pubmed">22393283</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Dec 17;31(1):49-57</Citation><ArticleIdList><ArticleId IdType="pubmed">23142300</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2006 Nov 1;194 Suppl 2:S111-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17163383</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2014 Sep 3;32(39):5041-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25045806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ther Adv Vaccines. 2015 Jul;3(4):97-108</Citation><ArticleIdList><ArticleId IdType="pubmed">26478817</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2012 Feb;19(2):128-39</Citation><ArticleIdList><ArticleId IdType="pubmed">22190399</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatric Infect Dis Soc. 2012 Mar;1(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23687572</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Microbes Infect. 2016 May 25;5:e51</Citation><ArticleIdList><ArticleId IdType="pubmed">27222326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 May;85(10):5027-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21367900</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2015 Jun;14(6):789-804</Citation><ArticleIdList><ArticleId IdType="pubmed">25968069</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 May;87(10):5985-93</Citation><ArticleIdList><ArticleId IdType="pubmed">23514880</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Sep 28;25(39-40):6845-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17728024</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2012 May 15;205(10):1562-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22448011</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2012 Sep 27;489(7417):526-32</Citation><ArticleIdList><ArticleId IdType="pubmed">22982990</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2017 Apr;23 (4):222-228</Citation><ArticleIdList><ArticleId IdType="pubmed">28216325</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2012 May;11(5):587-94</Citation><ArticleIdList><ArticleId IdType="pubmed">22827244</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2005 Nov 16;23(46-47):5404-10</Citation><ArticleIdList><ArticleId IdType="pubmed">16011865</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Aug 26;29(37):6408-18</Citation><ArticleIdList><ArticleId IdType="pubmed">21554915</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2007 Mar;13(3):426-35</Citation><ArticleIdList><ArticleId IdType="pubmed">17552096</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2015 Sep 18;349(6254):1301-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26303961</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Mar;82(6):1785-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3872457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2013 Jan;87(1):354-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23077314</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2009 Jan 1;199(1):49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">19032063</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2573-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22308500</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 Apr 3;31(14):1848-55</Citation><ArticleIdList><ArticleId IdType="pubmed">23376279</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Apr 15;52(8):1003-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21460314</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2006 Mar 6;24(10):1601-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16303215</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Jan 5;30(2):254-64</Citation><ArticleIdList><ArticleId IdType="pubmed">22085545</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2016 Feb 26;11(2):e0150146</Citation><ArticleIdList><ArticleId IdType="pubmed">26919288</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(1):e55516</Citation><ArticleIdList><ArticleId IdType="pubmed">23383214</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Jun;88(11):6019-30</Citation><ArticleIdList><ArticleId IdType="pubmed">24623430</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Jun;86(11):6179-88</Citation><ArticleIdList><ArticleId IdType="pubmed">22491456</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1999 May 4;17(18):2237-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10403591</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2011 Jun;90(3):227-30</Citation><ArticleIdList><ArticleId IdType="pubmed">21545812</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2008 Jun 25;3(6):e2517</Citation><ArticleIdList><ArticleId IdType="pubmed">18575608</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Virol. 2012 Apr;2(2):134-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22482710</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Virol. 2012;56(3):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23043596</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):E2514-23</Citation><ArticleIdList><ArticleId IdType="pubmed">24927560</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2012;7(10):e48322</Citation><ArticleIdList><ArticleId IdType="pubmed">23118984</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 2011 Jan 15;186(2):1022-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21169548</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccines (Basel). 2015 Feb 13;3(1):105-36</Citation><ArticleIdList><ArticleId IdType="pubmed">26344949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nanomedicine. 2016 Oct;12 (7):1909-1917</Citation><ArticleIdList><ArticleId IdType="pubmed">27112307</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 1997 Jun;15(8):865-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9234535</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 1985 Jun;66 ( Pt 6):1327-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3874261</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2015 Nov 27;33(48):6622-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26529070</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2010 Dec;16(12):1389-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21135852</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 May 19;26(21):2627-39</Citation><ArticleIdList><ArticleId IdType="pubmed">18395306</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Jun 1;201(11):1644-53</Citation><ArticleIdList><ArticleId IdType="pubmed">20423222</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013;8(3):e55435</Citation><ArticleIdList><ArticleId IdType="pubmed">23536756</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1989 Feb;86(3):1061-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2915973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2010 Dec;18(12):2182-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20877342</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2008 Jul;79(1):71-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18358544</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2009 Jan;3(1):37-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19453440</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Vaccine Immunol. 2012 Dec;19(12):1943-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23081815</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2012 Jul;55(1):19-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22441650</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2015 Sep;21(9):1065-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26301691</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18979-84</Citation><ArticleIdList><ArticleId IdType="pubmed">20956293</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):757-61</Citation><ArticleIdList><ArticleId IdType="pubmed">21187388</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2011 Jun 15;203(12):1729-38</Citation><ArticleIdList><ArticleId IdType="pubmed">21606531</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2011 Aug 12;333(6044):843-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21737702</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2010 Feb 26;6(2):e1000796</Citation><ArticleIdList><ArticleId IdType="pubmed">20195520</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2016 Jul 11;90(15):6771-6783</Citation><ArticleIdList><ArticleId IdType="pubmed">27194759</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2013 Dec 26;369(26):2564-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24224560</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2015 Dec 2;7(316):316ra192</Citation><ArticleIdList><ArticleId IdType="pubmed">26631631</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2017 May 26;91(12 ):</Citation><ArticleIdList><ArticleId IdType="pubmed">28356526</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000370 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000370 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28925296
|texte= Vaccine approaches conferring cross-protection against influenza viruses.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28925296" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a PandemieGrippaleV1
| This area was generated with Dilib version V0.6.34. |  |